Trial Profile
Efficacy of antitumor necrosis factor (infliximab or adalimumab) in patients with small bowel Crohn's disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 10 May 2016 New trial record